ACADIA Stock Soars (ACAD)

NEW YORK ( TheStreet) -- Shares of ACADIA Pharmaceuticals (Nasdaq: ACAD) have taken a tremendous swing upward. The stock is trading at $1.53 as of 3:45 p.m. ET, 20.1% above Tuesday's closing price of $1.27. Volume is at 1.2 million, 6.9 times the daily average of 171,500.

ACADIA has a market cap of $66.5 million and is part of the health care sector and drugs industry. Shares are up 17.6% year to date as of the close of trading on Tuesday.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on drug discovery and clinical development of novel treatments for central nervous system disorders. The company has a P/E ratio of three, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates ACADIA as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, reasonable valuation levels and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and a generally disappointing performance in the stock itself. You can view the full ACADIA Ratings Report.

See our top % gaining stocks list for other stocks that are soaring today, or get investment ideas from our investment research center.

Interested in other stocks that are soaring? Get free SMS text alerts sent to you when the action happens by texting SOAR to 95370 or select from multiple alert options.
null

If you liked this article you might like

Biotech M&A: Who's Next After Gilead-Kite?

'Longing' for Acadia Pharmaceuticals? Here's How to Play It

3 Housing Plays With Solid Earnings

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

Jana Partners Liquidates Whole Foods Stake After Engineering Industry-Transforming Sale To Amazon